Mirel (Reteplase)

Mirel (Reteplase) is a potent thrombolytic medication engineered to dissolve life-threatening blood clots during acute myocardial infarction. As a genetically modified tissue plasminogen activator (tPA), reteplase works by converting plasminogen into plasmin, an enzyme that breaks down fibrin and restores critical blood flow to the heart muscle during cardiac emergencies.

Reteplase is administered via intravenous injection in hospital and emergency room settings, typically delivered in two bolus doses under continuous cardiac monitoring. The medication must be administered as quickly as possible following the onset of heart attack symptoms—ideally within 12 hours—to maximize therapeutic effectiveness and minimize myocardial damage.

This medication is reserved exclusively for acute myocardial infarction treatment in controlled medical environments due to its potent clot-dissolving properties and potential for serious bleeding complications. Reteplase carries significant contraindications, including recent surgical procedures, active bleeding, uncontrolled severe hypertension, prior cerebrovascular events, and other conditions that increase hemorrhagic risk.

Mirel reteplase represents a critical intervention in emergency cardiac care, offering rapid restoration of coronary blood flow when administered promptly in appropriate hospital settings with full cardiac support and monitoring capabilities.